Catalent Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Catalent Inc (CTLT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Catalent Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4,422M vs 57,586M combined for its competitors (7.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-7.5% annualized vs trailing 12 months), vs decelerating (-11.2%) for its tracked peer group.
- Growth: Catalent Inc generated 4.2% revenue growth year over year in Q1 2024, vs 0.6% for its competitors combined.
- Profitability: Its -12.6% net margin compares with 14.2% for the peer group.
- Peer revenue share: Catalent Inc accounted for 7.4% of combined revenue among its tracked peer group, up from 7.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.26M compares with $0.35M for the peer group (0.8x).
- Structure: Catalent Inc operates in the following segments: PharmaConsumerHealth, Biologics.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CTLT Sales vs. its Competitors, Q1 2024
Catalent Inc reported revenue growth of 4.18 % year on year in Q1 2024, above its competitors' combined revenue growth of 0.60 %.
With a net margin of -12.61 %, Catalent Inc reported lower profitability than its competitors (14.21 %).
Catalent Inc generated 7.41 % of the combined sales of its peer group, up from 7.17 % a year earlier.
API endpoints for this dataset
Catalent Inc vs. its Competitors, Q1 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Catalent Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Catalent Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Catalent Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Catalent Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 4.2% for Catalent Inc. Catalent Inc's share of combined industry revenue moved from 0.20% to 0.20%, a loss of 0.01 percentage points.
Catalent Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Catalent Inc | No | Yes | No | No |
| Competitors combined (10) | ||||
| High-Confidence Competitors (3) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CTLT Stock Performance relative to its Competitors
CTLT Stock Performance relative to High-Confidence Competitors
CTLT Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cryoport inc | 282.9% | Outperformed |
| 2 | Immunoprecise Antibodies Ltd | 282.9% | Outperformed |
| 3 | Charles River Laboratories International inc | 282.9% | Outperformed |
| 4 | Alpha Teknova Inc | 282.9% | Outperformed |
| 5 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Catalent Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Catalent Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Catalent Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Catalent Inc |
11,553.36 | 4,422.00 |
 Thermo Fisher Scientific Inc |
257,755.96 | 47,351.00 |
 Charles River Laboratories International inc |
16,208.05 | 3,998.99 |
 Aptargroup inc |
9,140.95 | 3,991.23 |
 Corcept Therapeutics Inc |
8,965.34 | 963.65 |
 Marizyme Inc |
4,758.78 | 0.65 |
| SUBTOTAL | 310,781.28 | 62,008.49 |
Sign in to see all competitors of Catalent Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Catalent Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Catalent Inc's Competitors Named by the Company
Competitive relationships identified from Catalent Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Incannex Healthcare Inc | Company report | 85% |
| Societal Cdmo Inc | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Aptargroup inc | Company report | 85% |
| Charles River Laboratories International inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Avid Bioservices Inc | Company report | 85% |
| Alpha Teknova Inc | Company report | 85% |
| Cryoport inc | Company report | 85% |
| Evotec Se | Company report | 85% |
Company report basis, confidence, active dates and source counts for Catalent Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Catalent Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Catalent Inc | PharmaConsumerHealth 55.03 % |
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
| Charles River Laboratories International inc | Discovery and Safety Assessment 60.68 % |
| Aptargroup inc | Pharma 44.57 % |
| Cryoport inc | Life Sciences Services 58.40 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Catalent Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Catalent Inc | 11,553 | 261,657 | -24,438 |
| Thermo Fisher Scientific Inc | 257,756 | 378,808 | 56,712 |
| Charles River Laboratories International inc | 16,208 | 202,994 | -11,995 |
| Aptargroup inc | 9,141 | 285,088 | 19,118 |
| Corcept Therapeutics Inc | 8,965 | 1,320,064 | 221,411 |
| Marizyme Inc | 4,759 | - | - |
| PEERS TOTAL | 299,228 | 346,135 | 41,519 |
Catalent Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Catalent Inc | North America 64.32 % |
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Charles River Laboratories International inc | United States 55.12 % |
| Aptargroup inc | Europe 49.20 % |
| Cryoport inc | Americas 73.14 % |
| Alpha Teknova Inc | US 95.19 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Catalent Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 21.82 % | 37.89 % (avg) | -16.1 pp |
| Operating Margin | -2.04 % | industry median | +60.7 pp |
| EBITDA Margin | 9.68 % | -6.23 % (avg) | +15.9 pp |
| Capital Intensity (Capex / Revenue) | 6.78 % | 7.58 % (avg) | -0.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Catalent Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | 39.0x | 15.9x | +23.1x |
| P/B | 2.8x | 4.3x | -1.4x |
| Return on Equity | -10.88 % | industry aggregate | -21.22 % |
| Return on Invested Capital | -0.64 % | -9.83 % (avg) | 9.19 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Catalent Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 3.35 % | 21.29 % | 8.19 % | 9.70 % | 26.94 % | -20.10 % | 5.52 % | -13.38 % |
| Operating Margin | 10.27 % | 11.40 % | 10.81 % | 10.94 % | 13.83 % | 20.50 % | 13.30 % | -29.26 % |
| Return on Invested Capital | 5.85 % | 6.35 % | 5.10 % | 4.49 % | 4.93 % | 6.40 % | 4.13 % | -8.07 % |
| P/E | 33.9x | 79.8x | 35.9x | 67.8x | 56.7x | 39.6x | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Catalent Inc's Strategic Group Map
Catalent Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Catalent Inc's trailing-12-month revenue growth of 4.7% and operating margin of -2.0% compares with an average of 3.9% growth and -2.0% margin across its 8 closest peers by combined growth, margin and ROIC -- Catalent Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Catalent Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 6.78 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Catalent Inc's dedicated Suppliers and Customers pages, not here.
Catalent Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Catalent Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Catalent Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 60.7 points above the industry median.
Weaknesses
- Return on equity 21.2 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-7.5% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-11.2% annualized).
Methodology: see Methodology: SWOT Analysis.
Catalent Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Catalent Inc | 0.25 | 2.50 | 1.63 |
| Thermo Fisher Scientific Inc | 0.39 | 1.69 | 0.81 |
| Charles River Laboratories International inc | 0.18 | 1.34 | 0.78 |
| Aptargroup inc | 0.22 | 1.60 | 0.73 |
| Corcept Therapeutics Inc | 0.68 | 2.91 | - |
| Marizyme Inc | 0.00 | 0.03 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Catalent Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Catalent Inc | Q3 2024 | +4.2 % | - |
| Thermo Fisher Scientific Inc | Q3 2026 | +9.1 % | +6.2 % |
| Charles River Laboratories International inc | Q2 2026 | -2.7 % | - |
| Aptargroup inc | Q3 2026 | +6.0 % | -74.5 % |
| Corcept Therapeutics Inc | Q3 2026 | +64.0 % | +554.9 % |
| Marizyme Inc | Q3 2024 | - | - |
| PEERS TOTAL | +8.2 % | +75.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Catalent Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Catalent Inc | Q3 2024 | +3.6 % | -32.1 % |
| Thermo Fisher Scientific Inc | Q3 2026 | +133.0 % | +8.2 % |
| Charles River Laboratories International inc | Q2 2026 | - | -11.9 % |
| Aptargroup inc | Q3 2026 | +20.7 % | +10.1 % |
| Corcept Therapeutics Inc | Q3 2026 | +0.3 % | - |
| Marizyme Inc | Q3 2024 | - | - |
Catalent Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Catalent Inc | - | - | - |
| Thermo Fisher Scientific Inc | 6.29% | 7.46% | 13.32% |
| Charles River Laboratories International inc | - | - | - |
| Aptargroup inc | 5.20% | 5.99% | 10.09% |
| Corcept Therapeutics Inc | 18.09% | 22.08% | 22.88% |
| Marizyme Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Catalent Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Catalent Inc | - | 2.61 |
| Thermo Fisher Scientific Inc | 36.72 | 5.44 |
| Charles River Laboratories International inc | - | 4.05 |
| Aptargroup inc | 34.76 | 2.29 |
| Corcept Therapeutics Inc | 57.30 | 9.30 |
| Marizyme Inc | - | 7,368.71 |
| PEERS AVERAGE | 47.85 | 5.01 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.